SCHEDULE: FMR LLC Reports 15% Stake in Legend Biotech

FMR LLC, through its subsidiaries, has disclosed beneficial ownership of 15.0% of Legend Biotech Corp.'s common stock as of June 30, 2026.

Summary

• FMR LLC and its affiliates, including Abigail P. Johnson, have reported beneficial ownership of 57,996,198.37 shares of Legend Biotech Corp. common stock.
• This holding represents 15.0% of the class of securities.
• The filing is an amendment (No. 9) to a Schedule 13G, indicating a passive investment approach.
• The reporting date for this ownership stake is June 30, 2026.
• FMR LLC is classified as an investment adviser (IA) and a holding company (HC) for reporting purposes.
• Abigail P. Johnson is identified as a Director, Chairman, and CEO of FMR LLC, and members of the Johnson family are predominant owners of FMR LLC's voting shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but stable institutional ownership stake without immediate indications of aggressive buying or selling.

Positives

• Significant institutional ownership by a major financial entity (FMR LLC) suggests confidence in Legend Biotech's long-term prospects.
• The filing indicates a stable, passive investment strategy, which is generally viewed favorably by the market as it doesn't imply immediate pressure to sell.
• Abigail P. Johnson's leadership role at FMR LLC adds a layer of credibility to the investment.

Negatives

• The filing does not provide specific reasons for the ownership level, leaving the strategic intent open to interpretation.
• While a large stake, it does not represent a controlling interest, limiting FMR LLC's direct influence on corporate decisions.

Risks

• Potential for future changes in FMR LLC's investment strategy could lead to significant stock sales, impacting share price.
• The concentration of ownership among a few entities, including FMR LLC and potentially the Johnson family group, could influence market dynamics.
• Dependence on FMR LLC's continued passive investment approach for market stability.

Future Outlook

The filing itself is a historical disclosure of ownership as of a specific date (June 30, 2026) and does not contain forward-looking statements or guidance from Legend Biotech Corp. regarding its business operations or financial performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant institutional holdings, as reported in Schedule 13G filings, are common in the biotechnology sector, reflecting investor interest in companies with high growth potential. FMR LLC is a major institutional investor, and its substantial stake in Legend Biotech underscores the company's perceived value within the industry.

Comparison to Industry Standards

• FMR LLC's 15.0% stake in Legend Biotech is a substantial institutional holding, often seen in companies with significant market capitalization and growth prospects within the biotechnology sector.
• While specific comparable companies are not detailed in this filing, typical institutional investors in biotech include firms like Vanguard, BlackRock, and other large asset managers, who often hold similar percentage stakes in their portfolio companies.

Stakeholder Impact

• Shareholders: The significant stake held by FMR LLC may provide a degree of stability to the stock price, but also indicates a large block of shares that could be sold in the future.
• Management of Legend Biotech Corp.: Awareness of a major institutional investor's substantial holding can influence strategic decisions and communication efforts.
• Potential Investors: The filing confirms Legend Biotech as a company of interest to large institutional investors.

Next Steps

• Continued monitoring of FMR LLC's ownership levels for any changes that might indicate a shift in investment strategy.
• Observation of Legend Biotech Corp.'s operational and financial performance to assess the underlying value supporting the institutional investment.

Key Dates

Keywords

Legend Biotech, FMR LLC, Institutional Ownership, Schedule 13G, Common Stock, Investment Adviser, Abigail P. Johnson, Beneficial Ownership